Brief: Sio Gene Therapies Announces Dosing Of First GM1 Gangliosidosis Early Infantile Patient In Ongoing Phase 1/2 Study Of AXO-AAV-GM1 Gene Therapy

Sio Gene Therapies

09/09/2021 12:41

Sept 9 (Reuters) - Sio Gene Therapies Inc  SIOX.O :
    * SIO GENE THERAPIES ANNOUNCES DOSING OF FIRST GM1
GANGLIOSIDOSIS
EARLY INFANTILE (TYPE I) PATIENT IN ONGOING PHASE 1/2 STUDY OF
AXO-AAV-GM1 GENE THERAPY
    * SIO GENE THERAPIES INC - STUDY HAS NOW ENROLLED A TOTAL OF
NINE
PATIENTS ACROSS LOW-DOSE AND HIGH-DOSE COHORTS
    * SIO GENE THERAPIES - ON TRACK TO REPORT 12-MONTH TOPLINE
SAFETY,
BIOMARKER, EFFICACY DATA FROM TYPE II LOW-DOSE AXO-AAV-GM1
COHORT IN OCT 2021

Source text for Eikon:  ID:nGNX4ZTZ4p 
Further company coverage:  SIOX.O 

 ((Reuters.Briefs@thomsonreuters.com;))